ANN ARBOR, Mich., July 01, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced it has appointed Craig Thompson, Chief Executive Officer of Cerevance, to its Board of Directors. Mr.

Following the Galien Forum, Technology Networks spoke with Sanket Shah, president of Otsuka Precision Health, to learn how ...

The article indicates that the sudden appearance (or disappearance?) of polymorphs can derail clinical programmes. Such an example occurred in the development of the anti-glioma drug temozolomide, ...

CAMBRIDGE, Mass., June 18, 2025 /PRNewswire/ — Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase ...

Since the 2006 update of the American Heart Association (AHA)/American College of Cardiology Foundation (ACCF) guidelines on secondary prevention, 1 important evidence from clinical trials has emerged ...

Funding for The Best Times is provided by The Plough Foundation. Striving to do the greatest good, for the greatest number of people, since 1964.

The International Society of Oral Oncology-Multinational Association for Supportive Care in Cancer (ISOO-MASCC) and ASCO convened a multidisciplinary Expert Panel to evaluate the evidence and ...

9 following the 11th Circuit’s rejection of the FTC’s reverse payment prosecution against Schering-Plough. 10 Although the DOJ’s brief did not comment on the merits, it was viewed by many at the time ...

Schering-Plough Research Institute, 2015 Galloping Hill Road, Kenilworth, New Jersey 07033 and Dendreon Corporation, 3005 First Avenue, Seattle, Washington 98121 Article Views are the ...

The CheckMate 9DW trial met the primary endpoint of overall survival for nivolumab plus ipilimumab versus lenvatinib or sorafenib in the first-line setting for patients with unresectable ...

Individual donors gave Individual donors gave 167 large ($200+) contributions to Schering-Plough Corp PAC in the 2007-2008 election cycle. See the details.